Navigation Links
Leading the Site CTMS Market: Clinical Conductor CTMS Reaches 1,600 Sites
Date:8/29/2013

ROCHESTER, N.Y., Aug. 29, 2013 /PRNewswire/ -- Bio-Optronics, the developer of Clinical Conductor Site CTMS, is thrilled to announce the successful CTMS implementation at over 1,600 clinical research sites around the world, making it the most widely used clinical trial management system. Designed specifically for research sites, Clinical Conductor Site CTMS is the premier tool for clinical research sites.

Sites that have adopted the Clinical Conductor Site CTMS platform have seen dramatic improvements in their overall operational effectiveness; many sites have reported up to a 20% increase in overall efficiency, while showing a 30% increase in profitability while using the software.

Company Vice President and COO Maria Durkin states, "Clinical Conductor Site CTMS has revolutionized the way sites conduct trials. Our customers are meeting recruitment targets more quickly, improving financial performance and managing trial documentation efficiently.  Sites using Clinical Conductor are also differentiating themselves as successful research organizations that consistently meet deliverables and achieve results. We've seen our customers achieve significant growth in trials. We are proud to be working with them and appreciate the ongoing feedback that enables Clinical Conductor Site CTMS to continue to adapt and grow with the market's needs."

Clinical Conductor Site CTMS has helped research sites worldwide make a profound impact on the healthcare industry. Since its debut, Clinical Conductor Site CTMS has been used in nearly 40,000 trials and has tracked over 2 million trial patients, spanning single sites, multi-location sites, site networks and hospital departments. As Clinical Conductor Site CTMS continues to grow, we foresee additional ways in which researchers will be able to expand and optimize their businesses, while expediting delivery of critical new enhancements in medicine, through the use of this CTMS.

Created with the understanding that no two sites are the same, Clinical Conductor Site CTMS has been designed with extensive functionality capable of satisfying every trial management need while adapting to the specific needs of each research organization. Listening to our customers and adapting to their changing needs, coupled with many years of healthcare experience, Clinical Conductor is able to stay on the leading edge when it comes to providing research organizations the necessary tools for successful trial management. The success and experience with site customers has provided Bio-Optronics the knowledge to expand its portfolio with Clinical Conductor Enterprise, a unique CTMS that provides unparalleled project management, visibility and real-time collaboration for CROs, SMOs, AMCs and provider networks managing multiple research trials across multiple sites, research organizations and partners.

Clinical Conductor Site CTMS is the site-specific trial management solution from leading healthcare software and service provider Bio-Optronics. As a market leader with over 28 years of industry experience working with over 1,800 healthcare and life sciences organizations, Bio-Optronics produces a variety of products aimed at meeting the specific needs of each organization: Clinical Conductor Enterprise, a leading-edge CTMS for organizations managing multiple trials across multiple locations; Momentum Physician and Staff Scheduler,  the highly configurable, rule-based scheduling software; and Biopoint, a patient identification system designed to ensure the proper identification of patients and synchronization of treatment at hospitals and other long-term care facilities. Bio-Optronics and its products are recognized for consistent, unparalleled service and support that continuously ensures our products are exceeding client and market needs.

Bio-Optronics, +1 585-272-1960, www.bio-optronics.com; Kyle Ricketts, Marketing Specialist, kricketts@bio-optronics.com 


'/>"/>
SOURCE Bio-Optronics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
2. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
3. Centius – Partners with Engaged Nation– a Leading Gaming Industry Customer Loyalty Solution Provider to Help Maximize Customer Lifetime Value
4. GeneCell International’s Director of Operations, Jose Cirino, Organizes A Series of Educational Seminars with South Florida's Leading Obstetricians and Gynecologist
5. Medrio, a Leading EDC Provider for Clinical Research, Announces Its Latest Version, 8.1 with iPad Support, is Available Without Charge for Academic Researchers
6. Accel-KKR Makes Growth Equity Investment in Zinc Ahead, Leading Provider of Marketing Compliance Solutions for the Life Sciences Industry
7. Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes
8. Metabolix Executives to Present at Leading Industry Conferences
9. Medical Concierge Travel International launches in Tandem with Leading Medical Cost Containment Company, EME International aimed at Self-Funded and Insurance Companies
10. Alexandrias 499 Illinois Street in Mission Bay, San Francisco, Signs Anchor 97,700 Rentable Square Foot Lease with Leading Mid-Cap Life Science Company
11. Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016  BD (Becton, Dickinson and Company) (NYSE: ... announced the launch of the BD CLiC™ System during ... Meeting. --> --> ... providing cost effective NGS library preparation with limited operator ... integrated, next generation sequencing (NGS) library prep instrument, engineered ...
(Date:2/11/2016)... Inc. (NASDAQ: NBIX ) today announced its financial results for ... --> --> For the fourth quarter of ... $0.34 loss per share, compared to a net loss of $19.4 ... 2014. For the year ended December 31, 2015, the Company reported ... as compared to a net loss of $60.5 million, or $0.81 ...
(Date:2/11/2016)... -- Spectra BioPharma Selling Solutions (Spectra) is a new ... the experience, expertise, operational delivery and customer focus ... Created in concert with industry leading commercial experts, ... tactical needs of its clients by providing value-based ... and non-personal promotion. --> ...
(Date:2/11/2016)... BEACH, Florida , February 11, 2016 /PRNewswire/ ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), ... diagnostics, announced today that its Thermomedics subsidiary, which ... progress on its growth plan in January 2016, ... products distributors, increasing sequential monthly sales growth, and ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
Breaking Biology News(10 mins):